Ledyard National Bank Acquires 4,712 Shares of GSK plc (NYSE:GSK)

Ledyard National Bank lifted its stake in shares of GSK plc (NYSE:GSK) by 24.1% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 24,281 shares of the pharmaceutical company’s stock after acquiring an additional 4,712 shares during the period. Ledyard National Bank’s holdings in GSK were worth $993,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of GSK. Cohen Investment Advisors LLC bought a new position in shares of GSK during the 2nd quarter worth about $349,000. Blair William & Co. IL lifted its holdings in shares of GSK by 14.9% in the 1st quarter. Blair William & Co. IL now owns 23,493 shares of the pharmaceutical company’s stock worth $1,007,000 after purchasing an additional 3,044 shares in the last quarter. SG Americas Securities LLC increased its stake in GSK by 448.7% during the 1st quarter. SG Americas Securities LLC now owns 17,690 shares of the pharmaceutical company’s stock valued at $758,000 after purchasing an additional 14,466 shares in the last quarter. Royal Fund Management LLC raised its holdings in GSK by 87.0% during the third quarter. Royal Fund Management LLC now owns 42,456 shares of the pharmaceutical company’s stock worth $1,737,000 after buying an additional 19,758 shares during the last quarter. Finally, CreativeOne Wealth LLC bought a new position in shares of GSK in the first quarter valued at $235,000. 15.74% of the stock is owned by institutional investors.

Insider Buying and Selling at GSK

In other news, major shareholder Plc Gsk bought 2,791,930 shares of the firm’s stock in a transaction that occurred on Friday, September 27th. The shares were acquired at an average price of $8.00 per share, with a total value of $22,335,440.00. Following the acquisition, the insider now owns 16,775,691 shares of the company’s stock, valued at approximately $134,205,528. The trade was a 0.00 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 10.00% of the company’s stock.

GSK Trading Down 1.0 %

Shares of GSK stock opened at $38.17 on Tuesday. The firm has a market cap of $79.10 billion, a PE ratio of 13.83, a P/E/G ratio of 1.30 and a beta of 0.65. GSK plc has a 1 year low of $33.67 and a 1 year high of $45.92. The company has a debt-to-equity ratio of 0.99, a current ratio of 0.82 and a quick ratio of 0.54. The stock has a fifty day moving average price of $41.40 and a 200-day moving average price of $41.23.

GSK (NYSE:GSK) last issued its quarterly earnings results on Wednesday, July 31st. The pharmaceutical company reported $1.09 EPS for the quarter, beating analysts’ consensus estimates of $1.00 by $0.09. GSK had a return on equity of 51.48% and a net margin of 12.87%. The firm had revenue of $9.95 billion for the quarter, compared to analysts’ expectations of $9.49 billion. Equities research analysts anticipate that GSK plc will post 4.14 EPS for the current year.

GSK Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, October 10th. Shareholders of record on Friday, August 16th were paid a $0.3843 dividend. The ex-dividend date of this dividend was Friday, August 16th. This represents a $1.54 annualized dividend and a yield of 4.03%. This is an increase from GSK’s previous quarterly dividend of $0.38. GSK’s dividend payout ratio (DPR) is currently 55.80%.

Wall Street Analyst Weigh In

GSK has been the topic of several recent research reports. Barclays raised shares of GSK to a “hold” rating in a research report on Tuesday, August 27th. Argus upgraded GSK to a “strong-buy” rating in a report on Wednesday, August 7th. UBS Group lowered GSK from a “buy” rating to a “neutral” rating in a research report on Monday, July 8th. Jefferies Financial Group lifted their price objective on shares of GSK from $52.50 to $53.00 and gave the stock a “buy” rating in a report on Tuesday, July 2nd. Finally, Citigroup upgraded shares of GSK to a “strong-buy” rating in a report on Monday, June 24th. Four investment analysts have rated the stock with a hold rating, two have assigned a buy rating and four have issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $50.00.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.